All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The FDA cleared the accelerated approval application for Fuzeon, a first-in-class fusion inhibitor for HIV-1 developed by Trimeris Inc., and partner F. Hoffmann-La Roche Ltd. (BioWorld Today)